Review Article

Long-Term Outcomes of Thermal Ablation for Benign Thyroid Nodules: The Issue of Regrowth

Jung Suk Sim and Jung Hwan Baek

1Department of Radiology, Withsim Clinic, Seongnam 13590, Republic of Korea
2Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea

Correspondence should be addressed to Jung Hwan Baek; radbaek@naver.com

Received 21 March 2021; Revised 20 June 2021; Accepted 12 July 2021; Published 22 July 2021

Academic Editor: Rosaria Meccariello

Copyright © 2021 Jung Suk Sim and Jung Hwan Baek. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thermal ablation (TA) for benign thyroid nodules (BTNs) is widely accepted as an effective and safe alternative to surgery. However, studies on the long-term outcomes of TA have reported problems with nodule regrowth and symptom recurrence, which have raised the need for adequate control of regrowth. Therefore, a more complete TA with a longer-lasting treatment effect may be required. In this study, we review and discuss long-term outcomes and regrowth of BTNs following TA and evaluate factors affecting the long-term outcomes. We also discuss the management of regrowth based on long-term outcomes.

1. Introduction

Thermal ablation (TA) for benign thyroid nodules (BTNs) was introduced in the early 2000s with the clinical application of laser ablation (LA) and radiofrequency ablation (RFA), after which the efficacy and safety of TA were established [1, 2]. Since the 2010s, studies reporting >3 years of follow-up results of LA and RFA have been published [3, 4], and other modalities such as microwave ablation (MWA), bipolar RFA, and high-intensity focused ultrasound (HIFU) have begun to be used for the treatment of BTNs [5–9]. TA has now been widely used not only for the treatment of BTNs, but also for goiter, bilateral tumors, recurrent thyroid cancer, and papillary thyroid microcarcinoma [10–13].

The initially published studies reported relatively short-term follow-up, mainly of around 1 year, and usually considered successful treatment to be that achieving 50% or more volume reduction and symptom resolution [10]. However, with the publication of follow-up results over >2 years, nodule regrowth and symptom recurrence have been reported [14, 15]. Some patients showing recurrence were treated with additional TA, but some underwent surgery, which raises the need for adequate control of regrowth [16, 17]. Therefore, a more complete TA with a longer-lasting treatment effect is required as an alternative to surgery [18].

In this study, we review and discuss long-term outcomes and regrowth of BTNs following TA and evaluate the factors affecting the long-term outcomes. We also discuss the management of regrowth based on long-term outcomes.

2. Consensus of the Term “Long Term”

There is currently no consensus on the definition of “long-term follow-up”. Given that regrowth is clinically important after TA, the timing of regrowth can be a determinant of long-term follow-up [19]. According to previous studies, "long-term follow-up" varies from 2 to 5 years [3, 17, 20–23]. However, a meta-analysis and systematic review on the long-term outcomes of TA included studies with follow-up of >3 years [24, 25]. Regrowth is rarely mentioned in papers reporting results up to 1 year but is often mentioned in
papercwithfollow-upperiodsof＞2years.Severalstudies reportedagrowthrateof20%to30%afterRFAandL.A., andgrowthappearstooccurafter2orst3years,depending onthedegreeofcompleteseptreatmentofthenodulemargin [16,17,21,26–28].Inthiscontext,wesuggestthat3years isappropriateforthedescription“longterm”inrespectives tothefollow-upofBTNsftreatedwithTA.

3. Definition of Regrowth

Variousdefinitionsofregrowthhavebeensuggested, in- cludinganodulevolumearcreaseof＞50%comparedwith theminimumrecordedvolumew29,30,a nodule volume 20%largerthanthevolumear1yearaftertreatment[21], andvolumearcreaseovertheinitialnodulevolume[26].The definitionachievingthebiggestconsensustodateisinoduled volumeincreaseof＞50%comparedwiththemimum recordedvolumewestronglysuggestthatadefinition withfullagreementisnecessaryfortherelatingreasons:(1) standardizationofregrowthreporting,(2)validationof regrowthrates,and(3)developmentofamanagementplan forpatientswithregrowth.

Recurrencehasbeenuesedinterchangeablywith regrowth[23,31];sometimestousetomeansothat thenodulevolumehasincreasedagain4,14,32,whereasother times,itisusedtomeanthatthesymptomhasreappeared [17].

AnearlysignofregrowthwasproposedbySimet al.[16]. Nodules treated with TA were typically composed of two areas:acentrallylocatedhypochoicablatedvolume(Va) andaperipherallylocatedviablearea,whichisanunder- treatedareaaroundtheVa. Thetotalnodulevolume (Vt) isthesumoftheVaintovableareavolumn(Vv). Vv, whichispracticallyimpossibleтомeasure,canbecalculated bytheformulaVv=VT−Va(Figure1).Regrowthistyp- icallytheresultofthegrowthoftheVv.However,asaVv isgenerallysmall,ithaslittleinfluenceonchangeinVtshortly aftertheprocedure,whereasaVahaseagreatinfluenceon changeinVtasitisgenerallyabsorbedquicklyintheyear followingTA.Therefore,evenifVvregrowthoccurswithin2 yearsaftertheprocedure,itiscanbeoffsetbyVaaabsorption. Thus,ifVvistracedseparately,thenregrowthmaybedetected earlier,evenwhenVtisdecreasing(Figure1).AVv increasemaybeanearsignofregrowthandcanbe consideredapredictingfactorofregrowth;itwasreported thatavanincreaseprecedesregrowthby1year[16].

Itisworthwhileemphasizingthatrepeatcytologyor biopsyisrecommendedbecausenoduleregrowthcanbe apotentialsignofoverlookedmalignancy[4,19];however,its valueisdebatable.Haet al.[33]revealthatBTNs showingregrowthafterRFAdidnotshowcytomorphological alerationoranymalignanttransformationonbiopsy.

4. Factors Related to the Long-Term Outcomes: Nodule Factors

Regrowthfrommarginaulnderatreatedtissue,whichis usuallyobserved2orst3yearsaftertheprocedure,isclosely relatedtolong-termoutcomes[34].Thebaselinenodule volumeinfluencesboththegrowthrateandlong-term outcomes[35].TAcanbeusedforsymptomaticandcos- meticimprovementofdiffuseand/ormultinodulargoiter, buttheseseuseshaveadifferentcontextfromthisthetherview [12,13].VascularnodulesaresistanttoTAbecausethey dispersetheinputenergy[36].Duringfollow-up,thede- velopmentofvascularitycanleadtoregrowth[37].Nodules withacysticcomponentandspongiformnoduleshaveata tendencytoshowagreatervolumereductionratio(VRR) overboththeshortterm[36,38]andlongterm[32].

4.1. Baseline Nodule Volume. The baseline nodule volumewas a majorvariableaffectinglong-termoutcomessuspect respectively achieved VRR＞50%after1year,thegrowthrate,and normalizationofthyroidfunction[17,23].Theresultsofseveral studiessupportthisview,withthelargerthebaseline nodulevolume,thethehighegrateandlowerthe VRR. Sosome想起了thattherewasno correlationbetweenbaseline nodulevolumeandoutcomes, butstudiesmakingthisclaimappeartolowerinnumber andpresentaninferiorqualityofevidence[21,26,32,39]. Studiesfindingthatthebaseline nodulevolumeisasso- ciatedwithVRRaremorenumerous.Limet al.[4]reporte dthat,fornoduleswithabaselinevolume＜10mL,thefinal VRRwas94.5%afteranaverageof1.7treatments,whereas noduleslargerthan20mLhadafinalVRRof88.2%afteran averageof3.8treatments.Theirmultilinearregression analysisshowedthatinitialnodulevolume(P＜0.001)was anindependentfactorpredictingthefinalVRR.However,ap- propriatevolumereductioncanbeachievedinlargorthyroid nodulesthroughtheuseofmoretreatmentsessions.Dean- drea et al.[23]showedthatnoduleswithavolume＜10mL wereincreasedby82%,whereasnoduleswithavolume be- twee10and20mLandthosewithavolume＞20mL were reducedby75%and65%,respectively.

Bernardi et al.[17]foundassociationsbetweenbaseline volumeandretreatment;forRFA,abaselinevolumew22.1mL andayearVRR＜66%predictedretreatment, whereasforL.A,abaselinevolumew14.5mLandayear VRR＜54%predictedretreatment.However,theydidnotfindaclearassociationbetweenbaseline volumeand regrowth.

Gambleunghe et al.[35]andCesareo et al.[40]reportede dthatTAwaseffectivefortreatingautonomouslyfunctioning thyroidnodules,especiallywhenthebaselinevolumewas smallandthatnodulevolumeseemstosbesignificant predictivefactoroftheefficacyofTA.Ameta-analysisalso indicatedthatthebaseline nodulevolumewasassociated withtherateofthyroid-stimulatinghornenormalization [41].

4.2. Vascularity. NodulevascularityinfluencestheVRR, regrowthrate,andalong-termoutcomes[9,15,36].Blood vesselsinnodulesdispersetheheatgeneratedbyablation devices,creatingthesocalledheat-sinkeffect[2].Ahnet al. describedthevascularityofmarginavlabletissueasafactor influencingvolumereduction[42].Moreover,vascularityisalsoafactorinfluencingregrowth[37].Duringfollow-up,if
A nodule shows or develops vascularity, it has considerable potential for regrowth [14, 43]. Yan et al. reported that vascularity was an independent factor associated with regrowth [36], and Wang et al. reported that a patient group showing regrowth demonstrated more vascularity than a nonregrowth group [44].

**Figure 1:** A benign symptomatic thyroid nodule in a 36-year-old female treated with three sessions of radiofrequency ablation (RFA). (a) The nodule was in the patient’s left lower lobe. The longest diameter was 4.7 cm, and the volume was 20.6 mL. There was no vascularity in and around the nodule. (b) Longitudinal image of the RFA-treated nodule 1 month after the procedure. The total nodule volume (VT) was reduced to 14.5 mL and the longest diameter to 3.8 cm. The volume reduction ratio was 30%. Ablated tissue located in the central portion of the treated nodule (Va) is surrounded by the peripherally located small amount of remaining viable tissue (arrows). The dotted lines indicate the measurements for Va, which best represent the volume of the complex and irregularly shaped ablated area. There was no vascularity. At this time, Va was 11.2 mL, the viable volume (Vv) was 3.2 mL, and the initial ablation ratio was 84%. (c) Color Doppler image of the treated nodule 19 months after the procedure shows the development of vascularity in the nodule. VT had decreased to 6.8 mL, but Va (arrow) had regressed to 1.1 mL and Vv had increased to 5.7 mL. Such a Vv increase is an early sign that can predict regrowth, even while VT is decreasing. As regrowth was expected, the patient received a second RFA in the following month. (d) Thirty-four months after the second RFA, the nodule showed a Vv increase again, and a third RFA was performed. Five percent dextrose injected for hydrodissection can be seen as an anechoic area between the nodule margin and carotid sheath (*). The tip of the electrode (long arrow) is located near the veins of the nodule margin to achieve venous ablation. Air bubbles formed by ablation are compactly filling the venous lumen (arrows). (e) Ten months after the third RFA, the nodule had turned into a small scar-like region of tissue without vascularity. The VT was 0.4 mL with no demonstrable Vv.
5. Factors Related to Long-Term Outcomes: Technical Factors

Long-term outcomes differ depending on the modality used [24] and the energy delivered [17]. As it is not possible to ablate all nodule tissues in a single session of TA, a better long-term outcome can be achieved by applying a multiple-session treatment strategy [18]. Recently, techniques targeting the margin control have been introduced [9].

5.1. TA Modalities. Most studies comparing modalities report that VRR is influenced by the TA modality [45–47]. Although LA and RFA are generally known to be very effective and safe, prospective studies comparing them are currently limited. A randomized open-label parallel trial comparing LA with RFA at 6 months was reported. In this study, Cesareo et al. [45] concluded that RFA achieved a larger nodule volume reduction than LA. However, Mauri et al. [48] reported that RFA and LA are similarly feasible, safe, and effective for treating BTNs. RFA is faster than LA but requires significantly higher energy. In a Bayesian network meta-analysis, RFA achieved better VRR than LA (77.8% vs. 49.5%) [47]. Two meta-analyses and systematic reviews that compared the long-term outcomes of LA and LA reported that the final VRR of RFA was higher, at 92.2% vs. 43.3% at 3 years or more and 87% vs. 44% at 3 years [24, 25]. The Italian minimally invasive treatments of the thyroid group reported that both RFA and LA resulted in significantly reduced nodule volume but that RFA was superior to LA [17].

Ha et al. [47] and Cho et al. [24] claimed that the difference between RFA and LA in the final VRR depends on whether marginal undertreated tissue is controlled. RFA uses a moving-shot technique with internally cooled electrodes. Because of its high maneuverability, this device can ablate marginally located nodule tissue as much as possible while minimizing thermal damage to surrounding tissues [2, 49]. By contrast, with the laser delivery fibers used in LA, ablation of the margin may be incomplete because the range of treatment is concentrated in the center of the nodule [26].

There are reports of LA outperforming RFA at 1 year follow-up. In a propensity score matching analysis, Pacella et al. [50] showed mean nodule reduction at 12 months of 70% ± 19% in an LA group vs. 62% ± 22% in an RFA group. They mentioned that the operator’s skills could be crucial in determining the extent of nodule volume reduction, regardless of the technique used. Ben Hamou et al. [51] reported that the nodule volume had significantly decreased by 75.0% in an RFA group and 83.9% in an LA group at 18 months.

MWA and HIFU have only recently begun to be used, and long-term follow-up results are, therefore, rare. Monpeyssen et al. reported a VRR after HIFU of 33.3% at 2 years and 31.9% at 3 years [52], while Lang et al. [31] and Trimboli et al. [53] reported an average VRR at 2 year follow-up of 70.4% and 43.3%, respectively. HIFU has the advantage of being a truly noninvasive technique that does not require the insertion of electrodes or fibers through the patient’s skin [52] but has the disadvantage of requiring a deeper anesthesia or sedation level because it is more painful than RFA or LA [54]. To our knowledge, there has been no report of the results of MWA or BTNs after >2 years of follow-up. Articles comparing the efficacy of RFA and MWA after a 1 year follow-up period reported that the results were similar [46, 55].

5.2. Energy Delivered. Another factor affecting long-term outcomes is the energy delivered. Bernardi et al. [17] reported that RFA with a cutoff of 1360 J/mL predicted VRR > 50% and RFA with a cutoff of 918 J/mL predicted retreatment. Trimboli et al. [56] found that the energy delivered was significantly correlated with VRR in nodules < 10 mL at 1 year, and Deandrea et al. [57] demonstrated that delivering 756 J/mL and 2670 J/mL gave a probability of VRR > 50% in 50% and 99% of patients, respectively, at 1 year.

5.3. Multiple-Session Ablation. Additional VRR is gained through multiple-session treatment [4]. However, sufficient effects can be obtained only when the method and timing of the additional treatment are selected appropriately [16, 47]. Huh et al. reported a randomized trial comparing single-session vs. two-session RFA for benign nodules. Their results showed that single-session RFA achieved significant volume reduction and a satisfactory clinical response in most patients, but that additional RFA was effective in patients with a large nodule (>20 mL) or unresolved clinical problems [58]. Deandrea et al. reported no VRR gain from one or two lots of additional LA [3]. In a systematic review and meta-analysis of the efficacy of TA for benign nonfunctioning solid thyroid nodules, Trimboli et al. reported no significant difference in VRR between single- and multiple-session LA [25].

However, contrasting results have also been reported. Lim et al. achieved >90% VRR after 4 years through multiple-session RFA [4], and in their meta-analyses and systematic reviews, Ha et al. and Cho et al. found that the long-term VRRs of RFA were higher than those of LA. The authors argued that the reason the final VRR of RFA was higher is that it could effectively control marginally located viable tissue with multiple-session treatment [24, 47].

As in the report of Huh et al., when a nodule is large or clinical problems are not resolved, additional ablation gains further efficacy [58]. From our point of view, the differences in reported results are based on whether marginal undertreated tissue could be effectively controlled or not, and the main reason for differences in efficacy is the maneuverability of the device.

5.4. Recently Introduced Techniques for Margin Control. For it to be a comparable alternative to surgery, TA has to achieve sustainable efficacy, such as life-long problem resolution. For this, some advanced techniques were recently introduced [59]. Park et al. proposed an advanced RFA technique to control marginal regrowth that they named...
vascular ablation. Two different vascular ablation techniques are available: artery-first ablation and marginal venous ablation. The artery-first ablation technique can be applied to hypervascular thyroid nodules with a prominent feeding artery. However, the marginal venous ablation technique is useful for most thyroid nodules because thyroid nodules usually have marginal draining veins [9]. Offi et al. reported that the VRR of RFA after ablation of the feeding artery was higher than that of RFA using the conventional technique [36].

Hydrodissection is another important technique for improving safety during margin ablation. Injecting 5% dextrose between the nodule margin and the surrounding tissues can create a space that helps in achieving complete ablation of marginal nodule tissue (Figure 1) [9].

6. Conclusions
TA for BTN is effective and safe according to the reports of short-term follow-up studies, but as long-term outcomes have been announced, it is becoming evident that the problem of regrowth is important. We should understand that regrowth from marginal undertreated tissue is frequently reported 2–3 years after TA. To minimize regrowth, complete ablation of the nodule margin using advanced techniques and an understanding of the influencing factors are necessary. In patients with large nodules or incompletely resolved clinical symptoms, additional treatment is required to achieve a long-term satisfactory effect. We hope that this review may help establish TA as a long-lasting treatment method with comparable outcomes to surgery in clinical practice.

Data Availability
The data used to support the findings of this study are included within the article.

Conflicts of Interest
Jung Hwan Baek has been a consultant to two radiofrequency companies, STARmed and RF Medical, since 2017. Jung Suk Sim has nothing to declare.

References
[1] E. Papini, R. Guglielmi, G. Bizzarri et al., “Treatment of benign cold thyroid nodules: a randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up,” Thyroid, vol. 17, pp. 229–235, 2007.
[2] W. K. Jeong, J. H. Baek, H. Rhim et al., “Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients,” European Radiology, vol. 18, no. 6, pp. 1244–1250, 2008.
[3] H. Dassing, F. N. Bennedbaek, and L. Hegedüs, “Long-term outcome following interstitial laser photoagulation of benign cold thyroid nodules,” European Journal of Endocrinology, vol. 165, no. 1, pp. 123–128, 2011.
[4] H. K. Lim, J. H. Lee, E. J. Ha, J. Y. Sung, J. K. Kim, and J. H. Baek, “Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients,” European Radiology, vol. 23, no. 4, pp. 1044–1049, 2013.
[5] W. Yue, S. Wang, B. Wang et al., “Ultrasound guided percutaneous microwave ablation of benign thyroid nodules: safety and imaging follow-up in 222 patients,” European Journal of Radiology, vol. 82, no. 1, pp. e11–e16, 2013.
[6] H. Korkusuz, N. Fehre, M. Sennert, C. Happel, and F. Grünwald, “Early assessment of high-intensity focused ultrasound treatment of benign thyroid nodules by scintigraphic means,” Journal of Therapeutic Ultrasound, vol. 2, no. 1, p. 18, 2014.
[7] X.-L. Li, H.-X. Xu, F. Lu et al., “Treatment efficacy and safety of ultrasound-guided percutaneous bipolar radiofrequency ablation for benign thyroid nodules,” The British Journal of Radiology, vol. 89, no. 1059, Article ID 20150858, 2016.
[8] K. D. Kohlhase, Y. Korkusuz, D. Gröner et al., “Bipolar radiofrequency ablation of benign thyroid nodules using a multiple overlapping shot technique in a 3-month follow-up,” International Journal of Hyperthermia, vol. 32, no. 5, pp. 511–516, 2016.
[9] H. S. Park, J. H. Baek, A. W. Park, S. R. Chung, Y. J. Choi, and J. H. Lee, “Thyroid radiofrequency ablation: updates on innovative devices and techniques,” Korean Journal of Radiology, vol. 18, no. 4, pp. 615–623, 2017.
[10] D. G. Na, J. H. Lee, S. L. Jung et al., “Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations,” Korean Journal of Radiology, vol. 13, no. 2, pp. 117–125, 2012.
[11] H. K. Lim, S. J. Cho, J. H. Baek et al., “US-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: efficacy and safety in a large population,” Korean Journal of Radiology, vol. 20, no. 12, pp. 1653–1661, 2019.
[12] B. H.-H. Lang, Y.-C. Woo, I. Y.-H. Wong, and K. W.-H. Chiou, “Single-session high-intensity focused ultrasound treatment for persistent or relapsed graves disease: preliminary experience in a prospective study,” Radiology, vol. 285, no. 3, pp. 1011–1022, 2017.
[13] M. Ji Hong, J. H. Baek, Y. J. Choi et al., “Radiofrequency ablation is a thyroid function-preserving treatment for patients with bilateral benign thyroid nodules,” Journal of Vascular and Interventional Radiology, vol. 26, no. 1, pp. 55–61, 2015.
[14] J. H. Kim, J. H. Baek, H. K. Lim et al., “2017 Thyroid radiofrequency ablation guideline: Korean society of thyroid radiology,” Korean Journal of Radiology, vol. 19, no. 4, pp. 632–655, 2018.
[15] J. H. Baek, “Factors related to the efficacy of radiofrequency ablation for benign thyroid nodules,” Ultrasonomgraphy, vol. 36, no. 4, pp. 385–386, 2017.
[16] J. S. Sim, J. H. Baek, J. Lee, W. Cho, and S. I. Jung, “Radiofrequency ablation of benign thyroid nodules: depicting early sign of regrowth by calculating vital volume,” International Journal of Hyperthermia: The Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, vol. 33, no. 8, pp. 905–910, 2017.
[17] S. Bernardi, F. Giudici, R. Cesareo et al., “Five-year results of radiofrequency and laser ablation of benign thyroid nodules: a multicenter study from the Italian minimally invasive treatments of the thyroid group,” Thyroid, vol. 30, no. 12, pp. 1759–1770, 2020.
[18] J. S. Sim and J. H. Baek, “Long-term outcomes following thermal ablation of benign thyroid nodules as an alternative to surgery: the importance of controlling regrowth,” Endocrinology and Metabolism, vol. 34, no. 2, pp. 117–123, 2019.
[19] E. Papini, H. Monpeyssen, A. Frasoldati, and L. Hegedüs, “2020 European thyroid association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules,” European Thyroid Journal, vol. 9, no. 4, pp. 172–185, 2020.

[20] F. Magri, S. Chytiris, M. Molteni et al., “Laser photoacogulation therapy for thyroid nodules: long-term outcome and predictors of efficacy,” Journal of Endocrinological Investigation, vol. 43, no. 1, pp. 95–100, 2020.

[21] E. Papini, T. Rago, G. Gambelunghe et al., “Long-term efficacy of ultrasound-guided laser ablation for benign solid thyroid nodules. Results of a three-year multicenter prospective randomized trial,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 10, pp. 3653–3659, 2014.

[22] J. Aldea Martinez, “Radiofrequency ablation of thyroid nodules: a long-term prospective study of 24 patients,” Journal of Vascular and Interventional Radiology, vol. 30, pp. 1567–1573, 2019.

[23] M. Deandrea, P. Tribolli, F. Garino et al., “Long-term efficacy of a single session of RFA for benign thyroid nodules: a longitudinal 5 year observational study,” The Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 9, pp. 3751–3756, 2019.

[24] S. J. Cho, J. H. Baek, S. R. Chung, Y. J. Choi, and J. H. Lee, “Long-term results of thermal ablation of benign thyroid nodules: a systematic review and meta-analysis,” Endocrinology and Metabolism, vol. 35, pp. 339–350, 2020.

[25] P. Tribolli, M. Castellana, L. M. Sconfinenza et al., “Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: a systematic review and meta-analysis,” Endocrine, vol. 67, pp. 35–43, 2019.

[26] R. Valcavi, F. Riganti, A. Bertani, D. Formisano, and C. M. Pacella, “Percutaneous laser ablation of cold benign thyroid nodules: a 3 year follow-up study in 122 patients,” Thyroid, vol. 20, no. 11, pp. 1253–1261, 2010.

[27] G. Gambelunghe, F. Fede, V. Bini et al., “Ultrasound-Guided interstitial laser ablation for thyroid nodules is effective only at high total amounts of energy,” Surgical Innovation, vol. 20, no. 4, pp. 345–350, 2013.

[28] S. Bernardi, M. Cavallaro, G. Colombin et al., “Initial ablation ratio predicts volume reduction and retreatment after 5 years from radiofrequency ablation of benign thyroid nodules,” Frontiers in Endocrinology, vol. 11, Article ID 582550, 2020.

[29] B. R. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 26, no. 1, pp. 1–133, 2016.

[30] G. Mauri, C. M. Pacella, E. Papini et al., “Image-Guided thyroid ablation: proposal for standardization of terminology and reporting criteria,” Thyroid, vol. 29, no. 5, pp. 611–618, 2019.

[31] B. H. H. Lang, Y.-C. Woo, and K. W.-H. Chiu, “Two-year efficacy of single-session high-intensity focused ultrasound (HIFU) ablation of benign thyroid nodules,” European Radiology, vol. 29, no. 1, pp. 93–101, 2019.

[32] R. Negro and G. Greco, “Unfavorable outcomes in solid and spongiform thyroid nodules treated with laser ablation. A 5 year follow-up retrospective study,” Endocrine, Metabolic and Immune Disorders—Drug Targets, vol. 19, no. 7, pp. 1041–1045, 2019.

[33] S. M. Ha, J. Y. Shin, J. H. Baek et al., “Does radiofrequency ablation induce neoplastic changes in benign thyroid nodules: a preliminary study,” Endocrinology and Metabolism, vol. 34, no. 2, pp. 169–178, 2019.

[34] R. Cesareo, A. Palermo, V. Pasqualini et al., “Radiofrequency ablation for the management of thyroid nodules: a critical appraisal of the literature,” Clinical Endocrinology, vol. 87, no. 6, pp. 639–648, 2017.

[35] G. Gambelunghe, E. Stefanetti, R. Colella, M. Monacelli, N. Avenia, and P. De Feo, “A single session of laser ablation for toxic thyroid nodules: three-year follow-up results,” International Journal of Hyperthermia, vol. 34, no. 5, pp. 631–635, 2018.

[36] C. Offi, S. Garberoglio, G. Antonelli et al., “The ablation of thyroid nodule’s afferent arteries before radiofrequency ablation: preliminary data,” Frontiers in Endocrinology, vol. 11, 2021.

[37] J. H. Baek, “Factors related to the recurrence of benign thyroid nodules after thermal ablation,” International Journal of Hyperthermia, vol. 33, no. 8, pp. 957–958, 2017.

[38] G. M. Lee, J. Y. You, H. Y. Kim et al., “Successful radiofrequency ablation strategies for benign thyroid nodules,” Endocrine, vol. 64, no. 2, pp. 316–321, 2019.

[39] S. L. Jung, J. H. Baek, J. H. Lee et al., “Efficacy and safety of radiofrequency ablation for benign thyroid nodules: a prospective multicenter study,” Korean Journal of Radiology, vol. 19, no. 1, pp. 167–174, 2018.

[40] R. Cesareo, A. M. Naciuc, M. Iozzino et al., “Nodule size as predictive factor of efficacy of radiofrequency ablation in treating autonomously functioning thyroid nodules,” International Journal of Hyperthermia, vol. 34, no. 5, pp. 617–623, 2018.

[41] R. Cesareo, A. Palermo, D. Benvenuto et al., “Efficacy of radiofrequency ablation in autonomous functioning thyroid nodules. A systematic review and meta-analysis,” Reviews in Endocrine and Metabolic Disorders, vol. 20, no. 1, pp. 37–44, 2019.

[42] H. S. Ahn, S. J. Kim, S. H. Park, and M. Seo, “Radiofrequency ablation of benign thyroid nodules: evaluation of the treatment efficacy using ultrasonography,” Ultrasonography, vol. 35, no. 3, pp. 244–252, 2016.

[43] E. J. Ha, J. H. Baek, Y. Che et al., “Radiofrequency ablation of benign thyroid nodules: recommendations from the asian conference on tumor ablation task force,” Ultrasonography, vol. 40, no. 1, pp. 75–82, 2021.

[44] B. Wang, Z.-Y. Han, J. Yu et al., “Factors related to recurrence of the benign non-functioning thyroid nodules after percutaneous microwave ablation,” International Journal of Hyperthermia, vol. 33, no. 4, pp. 459–464, 2017.

[45] R. Cesareo, C. M. Pacella, V. Pasqualini et al., “Laser ablation versus radiofrequency ablation for benign non-functioning thyroid nodules: six-month results of a randomised, parallel, open-label, trial (LARA trial),” Thyroid, vol. 30, no. 6, pp. 847–856, 2020.

[46] D. M. Guo, Z. Chen, Y. X. Zhai, and H. H. Su, “Comparison of radiofrequency ablation and microwave ablation for benign thyroid nodules: a systematic review and meta-analysis,” Clinical Endocrinology, vol. 95, no. 1, pp. 187–196, 2021.

[47] E. J. Ha, J. H. Baek, K. W. Kim et al., “Comparative efficacy of radiofrequency and laser ablation for the treatment of benign thyroid nodules: systematic review including traditional pooling and bayesian network meta-analysis,” The Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 5, pp. 1903–1911, 2015.

[48] G. Mauri, L. Cova, C. G. Monaco et al., “Benign thyroid nodules treatment using percutaneous laser ablation (PLA)
and radiofrequency ablation (RFA),” *International Journal of Hyperthermia*, vol. 33, no. 3, pp. 295–299, 2017.

[49] J. H. Shin, J. H. Baek, E. J. Ha, and J. H. Lee, “Radiofrequency ablation of thyroid nodules: basic principles and clinical application,” *International Journal of Endocrinology*, vol. 2012, Article ID 919650, 2012.

[50] C. M. Pacella, G. Mauri, R. Cesareo et al., “A comparison of laser with radiofrequency ablation for the treatment of benign thyroid nodules: a propensity score matching analysis,” *International Journal of Hyperthermia: The Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group*, vol. 33, no. 8, pp. 911–919, 2017.

[51] A. Ben Hamou, E. Ghanassia, S. Espiard et al., “Safety and efficacy of thermal ablation (radiofrequency and laser): should we treat all types of thyroid nodules?” *International Journal of Hyperthermia: The Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group*, vol. 36, no. 1, pp. 1301–1309, 2020.

[52] P. Trimboli, F. Pelloni, F. Bini, F. Marinozzi, and L. Giovannella, “High-intensity focused ultrasound (HIFU) for benign thyroid nodules: 2-year follow-up results,” *Endocrine*, vol. 65, no. 2, pp. 312–317, 2019.

[53] M. Deandrea, P. Trimboli, A. Mormile et al., “Determining an energy threshold for optimal volume reduction of benign thyroid nodules treated by radiofrequency ablation,” *European Radiology*, vol. 31, no. 7, pp. 5189–5197, 2021.

[54] J. Y. Huh, J. H. Baek, H. Choi, J. K. Kim, and J. H. Lee, “Symptomatic benign thyroid nodules: efficacy of additional radiofrequency ablation treatment session—prospective randomized study,” *Radiology*, vol. 263, no. 3, pp. 909–916, 2012.

[55] J. S. Sim and J. H. Baek, “Unresolved clinical issues in thermal ablation of benign thyroid nodules: regrowth at longterm follow-up,” *Korean Journal of Radiology*, vol. 22, 2021.